SCHEMBL22386357

SCHEMBL22386357

CCCN1C(=O)/C(=C/c2ccc3c(c2)CCO3)S/C1=N\c1ccc(OC)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.58
▸ MAPT P10636 7/20 0.58
▸ MEN1 O00255 5/20 0.58
▸ KMT2A Q03164 5/20 0.58
▸ NPSR1 Q6W5P4 4/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ ALOX12 P18054 2/20 0.58
▸ RECQL P46063 2/20 0.58
▸ CYP1A2 P05177 2/20 0.58
▸ CYP3A4 P08684 2/20 0.58
▸ CYP2C9 P11712 2/20 0.58
▸ CYP2C19 P33261 2/20 0.58
▸ TDP1 Q9NUW8 2/20 0.58
▸ LMNA P02545 2/20 0.58
▸ HPGD P15428 2/20 0.58
▸ THRB P10828 1/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ CA9 Q16790 3/20 0.53
▸ MGAM O43451 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17309314 0.86 ALDH1A1 (0.61) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL17302233 0.75 CA9 (0.68) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL17302215 0.74 CFTR (0.51) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL17302214 0.74 CA9 (0.50) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL19096222 0.73 FAAH (0.67) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL19481512 0.73 CA9 (0.76) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL17309309 0.73 CA9 (0.76) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL12912674 0.71 S1PR3 (0.62) FAAH
SCHEMBL12912678 0.71 S1PR1 (0.62) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL12912685 0.70 S1PR1 (0.62) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3148541-B1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIV BERN (CH) 2020-09-02 — — EP disclosed
Send feedback